A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor
Cancer Research, ISSN: 1538-7445, Vol: 72, Issue: 7, Page: 1844-1852
2012
- 272Citations
- 283Captures
- 2Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations272
- Citation Indexes266
- 266
- CrossRef187
- Patent Family Citations6
- Patent Families6
- Captures283
- Readers283
- 283
- Mentions2
- News Mentions1
- News1
- References1
- Wikipedia1
Most Recent News
CAR T cells in a SNAP
Ten years ago, chimeric antigen receptors (CAR) promised to change the landscape of cancer therapy forever (1). With the help of genetic engineering, a person’s
Article Description
Adoptive immunotherapies composed of T cells engineered to express a chimeric antigen receptor (CAR) offer an attractive strategy for treatment of human cancer. However, CARs have a fixed antigen specificity such that only one tumor-associated antigen (TAA) can be targeted, limiting the efficacy that can be achieved because of heterogeneous TAA expression. For this reason, a more generalized and effective application of CAR therapy would benefit from the capability to produce large panels of CARs against many known TAAs. In this study, we show a novel strategy to extend the recognition specificity potential of a bioengineered lymphocyte population, allowing flexible approaches to redirect T cells against various TAAs. Our strategy employs a biotin-binding immune receptor (BBIR) composed of an extracellular-modified avidin linked to an intracellular T-cell signaling domain. BBIR T cells recognized and bound exclusively to cancer cells pretargeted with specific biotinylated molecules. The versatility afforded by BBIRs permitted sequential or simultaneous targeting of a combination of distinct antigens. Together, our findings show that a platform of universal T-cell specificity can significantly extend conventional CAR approaches, permitting the tailored generation of T cells of unlimited antigen specificity for improving the effectiveness of adoptive T-cell immunotherapies for cancer. ©2012 AACR.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84859383718&origin=inward; http://dx.doi.org/10.1158/0008-5472.can-11-3890; http://www.ncbi.nlm.nih.gov/pubmed/22315351; https://aacrjournals.org/cancerres/article/72/7/1844/578568/A-Universal-Strategy-for-Adoptive-Immunotherapy-of; http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-11-3890; https://syndication.highwire.org/content/doi/10.1158/0008-5472.CAN-11-3890; https://dx.doi.org/10.1158/0008-5472.can-11-3890; https://cancerres.aacrjournals.org/content/72/7/1844
American Association for Cancer Research (AACR)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know